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This issue of Gene Therapy focuses on recent developments and promising 
applications in nanoparticle delivery formulations. Gene therapy with viral vectors has 
achieved some notable successes in recent years for example, in the development of 
treatments for diseases such as immunodeficiencies, haemoglobinopathies, clotting 
disorders and retinal degeneration, with many other exciting developments in cancer 
with engineered T cells.  Gene therapy products are now finding their way to the 
market for treatment of rare diseases but most of this activity is focused on viral 
vectors. Non-viral vectors, as alternatives to viral vectors, offer advantages of safety 
and larger packaging capacity but clinical trials in diseases where liposomal vectors 
seemed particularly beneficial, such as lung disease of cystic fibrosis, have highlighted 
problems of efficiency and duration of gene expression. The most promising areas of 
clinical activity with non-viral nanoparticles is currently limited to siRNA delivery. 
However, recent developments in nucleic acid technologies including siRNA and 
oligonucleotides but also chemically modified mRNA and minicircle DNA, for which 
viral vectors are not an option, have led to a resurgence of interest in non-viral 
methods of delivery and nanoparticles in particular. Nanoparticles, as seen in the 
majority of articles in this issue, are rapidly emerging as de facto RNA delivery agents 
particularly for mRNA (Guan and Rosenecker), siRNA (Jones and Merkel; Scherman 
et al, Schiffelers et al) and RNA-based gene editing formulations (Wang et al.). 
The burgeoning field of CRISPR/Cas9 gene editing technologies also offers a 
range of new opportunities for nanoparticles that play to the strengths of these 
adaptable delivery systems as described in the article by Wang et al. in this issue. 
Formulations based on Cas9 mRNA and synthetic guide RNA or preassembled 
Cas9 ribonucleoprotein will require nanoparticle formulations and methodologies for 
delivery. The targeting of genetic loci with Cas9 by gRNA and the introduction of 
double strand breaks in the genome occur rapidly after transfection making long-
term expression redundant, and in fact, it is even thought to be undesirable to have 
persistent expression of Cas9 to limit off –target effects in the genome. Thus, 
transient expression, characteristic of nanoparticle transfection, once regarded as a 
limitation, may, in the context of gene editing, prove to be a strength in terms of 
specificity and efficiency. A further great advantage, is that even if a single dose 
does not achieve the desired level of gene disruption or repair, the low level of 
immunogenicity of most nanoparticle formulations means that repeated dosing may 
be performed until appropriate levels of gene modification are achieved. Such an 
approach would likely be challenging with viral vectors due to the adaptive immune 
system eradicating transduced cells. 
This increasing demand for nanoparticles will also likely lead to a better 
understanding of their optimal composition, structure and biological interactions with 
cells. The widespread use of just two viral vectors, where with a few exceptions 
lentivirus are used for ex vivo cell therapy and adeno-associated virus (AAV) for in 
vivo gene therapy, has undoubtedly benefited their rapid development and uptake for 
therapeutic uses. Nanoparticles, on the other hand, although generally limited to lipid 
or polymeric formulations, are often bespoke formulations to each laboratory. In this 
issue a wide range of formulations are described including emerging technologies 
such as graphene nanoparticles (Vincent et al. ) and exosomes (Schiffelers et al) as 
well as liposomal and polymeric formulations. Novel nanoparticles are still required 
for nucleic acid delivery which it will be important to characterise for their chemical 
and biophysical properties before clinical use. This requirement for multidisciplinary 
approaches in addition to the efficacy of viruses may have retarded the development 
of nanotechnologies so far but with the emergence of nucleic acids and therapeutic 
strategies that require their use, such studies acquire a new urgency.  
 Nanoparticles offer a wide range of applications in vivo and may be targeted 
by ligands or by their innate targeting properties for organs such as the liver where 
nanoparticles are most advanced in their clinical development although other targets 
such as inflammatory joints may be targeted systemically while the eye can be 
targeted by direct delivery routes (Scherman et al). A great deal of nanoparticle 
development is targeted towards cancer therapies and an example of that is 
described by Jones and Merkel in this issue in developing siRNA therapies for breast 
cancer. A challenge here is enabling the nanoparticle to avoid the liver after systemic 
delivery since many such formulations naturally accumulate in highly vascularised 
organs including liver, lung, spleen, reducing tumour targeting capacity.  
Despite the successes with viral vectors, challenges remain including 
overcoming the innate and adaptive immune responses to viruses and concerns 
over random integration leading to insertional oncogenesis with lentiviral vectors 
while arguments over links between AAV and liver cancer persist. Nanoparticles 
offer the opportunity to overcome such limitations provided their efficiency levels are 
sufficient and moreover expand the usefulness of new nucleic acid technologies in 
developing therapeutics. The reviews in this issue on new nanoparticle formulations, 
approaches to nucleic acid delivery and therapeutic strategies are therefore a timely 
reminder of the potential of such systems. 
